CMS Reinstates NovoCure's Billing Privileges Retroactively, Reversing Prior Revocation
NVCR sits 29% above its 52-week low of $9.82.
Summary
NovoCure announced that CMS has rescinded the prior revocation of its U.S. subsidiary's billing privileges, reinstating them retroactively to December 17, 2025, and mitigating a significant operational risk.
Key Events · Legal and Risk Events · NVCR
-
CMS Billing Privileges Reinstated
The Centers for Medicare & Medicaid Services (CMS) rescinded the revocation of Novocure Inc.'s billing privileges, reinstating them retroactively to December 17, 2025.
-
Reversal of Prior Revocation
This action reverses the previous revocation, which was disclosed on February 5, 2026, and was attributed to an administrative re-validation issue, not a substantive failure.
-
No Expected Revenue Impact
The company continued to provide services during the period of ineligibility and believes there will be no ultimate impact on its ability to recognize revenue for these services.
Analysis · NVCR · Industrial Applications And Services
This filing reports a critical positive development for NovoCure, as the Centers for Medicare & Medicaid Services (CMS) has rescinded the prior revocation of its U.S. subsidiary's billing privileges. The reinstatement, effective retroactively to December 17, 2025, directly reverses the significant negative news disclosed on February 5, 2026. This action removes a major operational and financial overhang, ensuring the company can continue to bill for its services to Medicare patients without interruption and expects no impact on revenue recognition. This is a substantial de-risking event for the company.
At the time of this filing, NVCR was trading at $12.71 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $9.82 to $22.30. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.